Mayne Pharma to sell international unit to Evaris Pharma for $55.5 million
ADELAIDE: Mayne Pharma Group Ltd. said Friday it has agreed to sell its international segment to Evaris Pharma for $55.5 million in cash, completing its transformation into a specialty pharmaceutical company focused entirely on the United States. The ASX-listed company…